Source: International Congress 2015 – IPF: from bench to bedside
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Xiaoping Long (Essen, Germany), Xiaoping Long, Ulrich Costabel, Xuan He, Thomas E. Wessendorf, Dirk Theegarten, Josune Guzman, Francesco Bonella. Effect of nintedanib on the release of angiogenic/angiostatic cytokines by alveolar macrophages (AMs) in interstitial lung diseases (ILD). Eur Respir J 2015; 46: Suppl. 59, 3054

Member's Comments

No comment yet.

Related content which might interest you: Effect of pirfenidone (PFD) on cytokine/chemokine release from alveolar macrophages (AMs) in interstitial lung diseases (ILD): Preliminary results Source: Annual Congress 2013 –Diffuse pulmonary fibrosis Year: 2013 Pirfenidone suppresses proinflammatory and antiangiogenetic cytokine production by alveolar macrophages (AMs) in idiopathic non specific interstitial pneumonia (iNSIP) Source: International Congress 2014 – ILDs 2 Year: 2014 Thalidomide reduces IL-18, IL-8 and TNF-α release from alveolar macrophages in interstitial lung disease Source: Eur Respir J 2006 Oct 01;28(4):824-831 Year: 2006 Circulating monocytes from interstitial lung disease patients show an activated phenotype Source: International Congress 2016 – ILD: from the bench to the bedside Year: 2016 Inhibition of profibrotic signaling in fibroblasts from patients with idiopathic pulmonary fibrosis (IPF) by histone deacetylase-inhibitors (HDACi) or the IPF drug pirfenidone Source: International Congress 2014 – ILDs 1 Year: 2014 Effect of cigarette smoking on alveolar macrophages (AM) and lymphocytes (AL) apoptosis in selected interstitial lung diseases (ILD) Source: Annual Congress 2008 - Role of bronchoalveolar lavage in studying the pathophysiology of interstitial lung disease Year: 2008 Inhaled sargramostim and whole lung lavage (WLL) as therapy of autoimmune pulmonary alveolar proteinosis (aPAP) Source: International Congress 2016 – Orphan diseases I Year: 2016 Role of macrophage activation in type II alveolar cells transplantation for the treatment of idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Translational studies in chronic repair and remodelling in the lung Year: 2013 Alveolar lymphocytes (AL) apoptosis in interstitial lung diseases (ILD). Increased AL apoptosis rate in idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2009 - Pathogenesis of pulmonary fibrosis Year: 2009 Uncoupling the pro-fibrotic effects of TGF-beta1 versus tissue hardening in lung fibroblasts Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities Year: 2013 The effect of nintedanib compared to pirfenidone on proliferation of lung fibroblasts from patients with IPF Source: International Congress 2015 – Interstitial lung diseases II Year: 2015 Nintedanib prevents IL-1beta-stimulated proliferation of primary human lung fibroblasts from patients with idiopathic pulmonary fibrosis or from control donors Source: International Congress 2014 – ILDs: pathogenesis and clinical features Year: 2014 Effect of nintedanib, pirfenidone, N-acetylcysteine and their combinations on cultured myofibroblast-type cells derived from patients with asbestosis and idiopathic pulmonary fibrosis Source: International Congress 2015 – Airway remodelling: recent developments Year: 2015 The role of macrophages in interstitial lung diseases Source: Eur Respir Rev, 26 (145) 170009; 10.1183/16000617.0009-2017 Year: 2017 SMAD2 mRNA expression is upregulated in fibrosing interstitial lung diseases (ILDs) Source: International Congress 2015 – Pulmonary fibrosis: mechanisms of disease Year: 2015 Whole lung lavage efficacy in pulmonary alveolar proteinosis (PAP) is influenced by the infusion volume? Source: International Congress 2015 – IIPs: orphan Year: 2015 Reduced anti-oxidant and increased inflammatory status in interstitial lung diseases (ILD) Source: Eur Respir J 2007; 30: Suppl. 51, 110s Year: 2007 M2 polarized alveolar macrophages in pulmonary fibrosis Source: Annual Congress 2005 - Pulmonary hypertension and fibrosis: novel mechanisms Year: 2005 Pulmonary alveolar proteinosis (PAP) in exogenous toxic alveolitis (ETA) patients Source: International Congress 2015 – Occupational disease: clinical cases and series Year: 2015 A mechanism for acceleration of GM-CSF autoantibody (GMAb) production in autoimmune pulmonary alveolar proteinosis (aPAP) Source: International Congress 2014 – Molecular pathogenesis of pulmonary inflammatory diseases (COPD, asthma and ILD) Year: 2014